Who participates in R&D subsidy programs? The case of spanish manufacturing firms.

Empirical evidence on the effectiveness of R&D subsidies to firms has produced mixed results so far. One possible explanation is that firms and project selection rules may be quite heterogeneous both across agencies and across industries, leading to different outcomes in terms of the induced additional private effort. Here we focus on the participation stage. Using a sample of Spanish firms, we test for differences across agencies and industries. Our results suggest that firms in the same industry face different hurdles to participate in different agencies’ programs, that participation patterns may reflect a combination of agency goals, and that patterns differ across high-tech and low-tech industries.

Contribuição ao estudo do gênero Phaenicia (R. D., 1863): (Diptera, Calliphoridae)

The author redescribes four species of Phaenicia refered to Brazil: P. sericata (Meigen), P. pallescens (Shannon), P. mexicana (Macquart) and P. eximia (Wiedemann). A new species, P. japuhybensis from the State of Rio de Janeiro, was also studied.

Capacidade receptora de Salmonella typhi A fatores R*1

Estudando a incidência de fatores infecciosos de resistência, em amostras de Salmonella, foi verificado apresentarem as amostras de S. typhi uma fraca habilidade receptora inicial a esses fatores.

Formas de cultura de Trypanosoma rotatorium Mayer, 1843: isolado da rã Leptodactylus ocellatus do Brasil

Os autores estudaram o comportamento "in vitro" do Trypanosoma encontrado nas rãs brasileiras, visando critérios adicionais na caracterização específica deste grupo. Utilizaram diferentes meios de cultura (NNN, Novy e Mac Neal, SNB 9 de Diamond 1954, Boné & Steinert, 1956 Boné & Parent 1963 e Halevy & Gisry 1964) no isolamento do Trypanosoma rotatorium encontrado com certa freqüência na rã Leptodactylus com larga distribuição na região Neotropical. Observamso que o comportamento do T. rotatorium das rãs desta região em meios de cultura mostra características bem diferentes daquelas observadas com tripanosomas de outras regiões, quer seja pela dificuldade de manutenção em subcultura, quer pelas formas de divisão desenvolvidas. Empregamos os mesmos meios de cultura utilizados nos isolamentos dos tripanosomas de rã da Europa e como pode ser visto no Quadro I os resultados obtidos com material da região Neotropical são concordantes, surgerindo, pelo menos uma variação dentro da espécie.

A imunidade na febre tifóide I. A vacinação anti-tifoídica de Wright, 1896 a 1979

A presente revisão aborda a literatura disponível sobre a vacinação anti-tifoídica. Sentiu-se desde o início a falta de um modelo experimental adequado para avaliar a potência da vacina e somente dados imcompletos e parciais foram obtidos de modelos humanos e animais em relação aos mecanismos imunológicos básicos da resposta à vacinação. Por esta razão um grande número de diferentes métodos foram propostos e usados, fornecendo variações em vários aspectos, tais como: a) tipo de amostra bacteriana utilizada no preparo da vacina; b) métodos de preparo (germes mortos por aquecimento e adição de preservativo, por éter, álcool, acetona, lisados bacterianos, germes vivos atenuados, etc.); c) composição da vacina; d) vias de inoculação (intradérmica, subcutânea, oral, etc.); e) variação do número de microrganismos; d) variação na dose e/ou intervalo entre as doses. Muitos ensaios de campo não foram conclusivos. Foi considerado que estes ensaios iniciais não tiveram controles adequados os quais foram introduzidos posteriormente em ensaios bem planejados, e patrocinados pela Organização Mundial da Saúde em várias partes do mundo (Iugoslávia, Polônia, União Soviética, ìndia e Condado de Tonga). Os dados disponíveis de tais ensaios permitiram as seguintes conclusões: a) a vacina inativada por etanol foi de pouco ou nenhum valor profilático; b) algumas vacinas inativadas ofereceram significante proteção; c) a vacina inativada por acetona é mais eficaz; d) não há proteção para as S. paratyphi A e B nas doses empregadas na TAB. Quando empregada a S. paratyphi B em doses maiores, esta proteção é obtida; e) os testes em animais de laboratórios não podem ser completamente correlacionados com a efetividade no homem bem como o título de anticorpos para os antígenos H, o e Vi; f) uma dose (0,5 a 1 ml de uma suspensão contendo 10*9 bactérias por ml) da vacina inativada por acetona da razoável proteção por um curto período, enquanto duas doses (intervalo de 4 semanas) dão maior proteção e por tempo mais longo; g) a proteção oferecida pela vacinação é maior nos jovens que nos adultos; h) a vacina oral inativada (Typhoral) não oferece proteção mesmo em doses elevadas. Algumas experiências com animais (camundongos, chimpanzés) e voluntários humanos indicaram que uma melhor proteção foi obtida com vacinas vivas atenuadas. Contudo em tais experiências houve persistência tanto da amostra vacinante como da amostra desafio e ainda uma relação significante entre a amostra da vacina rugosa utilizada para imunização e lesões renais abacterianas de natureza desconhecida.

Gorgorhynchus Trachinotus n.sp. and new host records for Dollfusentis Chandleri Golvan, 1969 (Paleacanthocephala, Echinorhynchoidea)

Gorgorhynchus trachinotus recovered from the intestine of trachinotus goodei Jordan & Evermann, 1896 is proposed as a new species and three new host records are reported for Dollfusentis chandleri Golvan, 1969.

Anti-doping testing at the 2008 European football championship.

Big sports events like the 2008 European Football Championship are a challenge for anti-doping activities, particularly when the sports event is hosted by two different countries and there are two laboratories accredited by the World Anti-Doping Agency. This challenges the logistics of sample collection as well as the chemical analyses, which must be carried out timeously. The following paper discusses the handling of whereabouts information for each athlete and the therapeutic use exemption system, experiences in sample collection and transportation of blood and urine samples, and the results of the chemical analysis in two different accredited laboratories. An overview of the analytical results of blood profiling and growth hormone testing in comparison with the distribution of the normal population is also presented.

Estudo da ação do moluscocida (Bayluscide-SRB) da Dynatech R/D Company em lagos do nordeste brasileiro - Sergipe, Brasil

To study the action of molluscicide nine ponds were selected: 3 of them lying in Maruim municipality, 29 km far from north Aracaju, the State capital, and 6 ponds in Itabaianinha municipality, 118 km far from south Aracaju. This study was carried out for 16 months. Environmental parameters observed were those thought to have any influence on the planorbids and/or the molluscicide: water temperature, transparence, salinity, pH, dissolved oxygen, CO2, and the nutrients-phosphorus, nitrogen, potassium and calcium. Plancton microorganisms were also considered to observe Bayluscide action on them. SRB was used in a concentration of 6.25 kg per 1.000 [cubic metres] water, to achieve 1.0 ppm Bayluscide concentration according to the producer's instruction in Massachussett-USA.

Assessing the assignation of public subsidies: Do the experts choose the most efficient R&D projects?

The implementation of public programs to support business R&D projects requires the establishment of a selection process. This selection process faces various difficulties, which include the measurement of the impact of the R&D projects as well as selection process optimization among projects with multiple, and sometimes incomparable, performance indicators. To this end, public agencies generally use the peer review method, which, while presenting some advantages, also demonstrates significant drawbacks. Private firms, on the other hand, tend toward more quantitative methods, such as Data Envelopment Analysis (DEA), in their pursuit of R&D investment optimization. In this paper, the performance of a public agency peer review method of project selection is compared with an alternative DEA method.

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.